Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
INTRODUCTION

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started by the end of December in Wuhan (China), and was declared a pandemic a couple of months later. Belgium went into lockdown on March 18th, after the first case was diagnosed on February 4th. Meanwhile, in Belgium, 57,342 people tested positive, and there were so far 9,312 deaths (until May 24th).

Patients with solid organ transplants (SOTs) may be more susceptible to infection with the virus because of their immunosuppressive drug treatment. Indeed several case reports and small case series of COVID-19 infection after SOT have been published, but data after lung transplantation are still limited. Aigner et al reported a single case report of COVID-19 in a lung transplant patient, who was discharged on day 21. Pereira et al included 17 lung transplant patients in their series of 90 SOT patients with COVID-19. However, they made no separate analysis of this particular patient group. In a Swiss SOT cohort, 1 of 21 patients was a lung transplant patient and the authors concluded that overall the clinical manifestations in SOT patients are similar to those in the general population. In the present article, we report our experience with 10 consecutive lung transplant patients with a PCR-proven, symptomatic COVID-19 infection.

CASE SERIES

Between March 18 and May 24, a total of 10 symptomatic lung transplant patients (1.5% of our total cohort of 680 lung transplant patients in follow-up) were diagnosed with SARS-CoV-2. In 8 of 10 patients the nasopharyngeal swab was real-time PCR positive, whereas in the remaining 2 patients a bronchoalveolar lavage (BAL) confirmed the diagnosis, after a negative nasopharyngeal swab. Eight of 10 patients needed hospital admission, of whom 1 was in the intensive care unit. He died after 2 weeks from multiple organ failure. The remaining nine patients recovered. Cell cycle inhibitors were withheld in all patients, whereas the calcineurin inhibitor and corticosteroids were continued at the same dose, with an acceptable outcome.

KEYWORDS
clinical research/practice, immunosuppressant, infection and infectious agents – viral, infectious disease, lung transplantation/pulmonology
with BAL was performed to exclude other causes for the bilateral ground glass opacities on CT scan.

Characteristics of the patients, who all underwent a double lung transplantation at a median of 26 months before diagnosis (range 6-190 months), are shown in Tables 1 and 2. They were all admitted for monitoring because of their symptoms and fear of progression of the disease.

All patients were at least on a double immunosuppressive regimen with a calcineurin inhibitor (CNI) and corticosteroids (CS), six took an additional cell cycle inhibitor (four mycophenolate mofetil [MMF], and two azathioprine); one patient was taking additional everolimus. All patients received azithromycin, 250-500 mg, 3 times a week, as standard of care in our center.

Median C-reactive protein (CRP) level decreased from 92.2 mg/L at initial presentation to 5.3 mg/L at discharge. D-dimers and interleukin-6 levels were not routinely measured. In four patients, ferritin was available (patients 6, 7, 9, and 10) and it was increased in three patients (range 96-1360 µg/mL), with the highest value (1360 µg/mL) in Patient 6. Three patients were treated for diabetes (two with insulin and one with oral treatment), and five for arterial hypertension. In all patients, respiratory cultures (bacterial, fungal) and other viral PCRs at time of diagnosis were negative.

One of the patients (no. 6) was immediately admitted to the intensive care unit (ICU), initially treated with high flow 100% oxygen, but needed intubation and ventilation 2 days later because of a very low oxygen saturation. Intermittent prone ventilation was used. His CT scan showed very prominent ground glass opacities, covering 50%-70% of both lungs. He received empiric meropenem, hydroxychloroquine, azithromycin (500 mg every day for 5 days), full-dose anticoagulation, and tocilizumab. Remdesivir was not used as it is not available in Belgium. He developed multiple organ failure and died after 13 days. The other seven patients were all admitted to a regular COVID-19 unit and treated with supplemental oxygen, empiric intravenous broad spectrum antibiotics, and hydroxychloroquine (400 mg every 12 hours for the first day, then two times 200 mg per day for 5 days), and we continued azithromycin (500 mg for 5 days), with daily QTc monitoring. They all gradually improved and were discharged home after 8.5 days (range 3-15 days).

One of the ambulatory patients (no. 8), was admitted to the hospital 6 weeks after her first positive nasopharyngeal swab, because of recurrence of high fever since 48 hours, dyspnea, tachypnea, cough, and desaturation (88%). Her nasopharyngeal swab remained positive (cycle threshold initially 16.2, at admission 16.9), a CT scan demonstrated extensive bilateral ground glass opacities (>50%), and the BAL (to exclude other causes) was also positive for SARS-CoV-2 (with a cycle threshold of 20.3), without any other positive viral PCR or bacterial/fungal cultures, despite the presence of 84% neutrophils in the BAL cell differential count. She was treated as described above with hydroxychloroquine, an increased dose of azithromycin, and empiric Rocephin, and she was discharged after 18 days. At that time, her nasopharyngeal swab remained positive, with a cycle threshold of 24.1.

In all patients, CNI and CS were continued at the same dose to maintain their normal calcineurin blocker trough level, whereas cell cycle inhibitors were stopped. No steroid bolus was administered.

### DISCUSSION

Although several case reports and small case series have been published of COVID-19 infection after SOT,1-6 there are only limited data on lung transplant patients.7-9 We report on our

---

**TABLE 1** Clinical characteristic of the 10 patients

| Patient number | Age (y), M/F | Disease | POM | IS regimen | Symptoms | O₂ saturation | Outcome, LOS (d) |
|----------------|-------------|---------|-----|------------|----------|---------------|-----------------|
| 1              | 44, F       | Non-CF Brect | 28  | FK/CS      | Fever, cough, pain | 99%            | Recovered, 3 d  |
| 2              | 61, F       | COPD     | 70  | FK/AZA/CS  | Dyspnea | 89%           | Recovered, 7 d  |
| 3              | 66, F       | COPD     | 36  | FK.EVE/CS  | Dyspnea, fever | 97%           | Recovered, 13 d |
| 4              | 62, F       | COPD     | 24  | FK/CS      | Fever    | 96%           | Ambulatory, recovered |
| 5              | 23, M       | OB       | 6   | FK/MMF/CS  | Fever, cough, dyspnea | 96%          | Recovered, 6 d  |
| 6              | 58, M       | Non-CF Brect | 190 | FK/MMF/CS  | Fever, cough, dyspnea | 72%          | ICU, died, 13 d |
| 7              | 64, F       | COPD     | 19  | FK/CS      | Nausea, vomitus | 95%           | Recovered, 9 d  |
| 8              | 20, F       | CF       | 13  | CSA/CS     | Fever, Cough | 99%           | Ambulatory, recovered^* |
| 9              | 67, F       | COPD     | 150 | FK/MMF/CS  | Fever, diarrhea | 95%           | Recovered, 8 d  |
| 10             | 60, M       | COPD     | 14  | FK/AZA/CS  | Fever, dyspnea | 96%           | Recovered, 15 d |

Abbreviations: AZA, azathioprine; Brect, bronchiectasis; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; CS, corticosteroids; CSA, cyclosporine; EVE, everolimus; FK, tacrolimus; LOS, length of stay; MMF, mycophenolate mofetil; OB, obliterative bronchiolitis; POM, postoperative month.

^*This patient was later hospitalized because of recurrent and more severe disease and was discharged after 18 d.
initial experience with 10 lung transplant patients with COVID-19, among a total cohort of 680 patients in follow-up at our center (1.5%). During the same time period, 23 lung transplant patients who had to undergo an elective bronchoscopy, either as surveillance or because of a decline in Forced expiratory volume in 1 second, and who were otherwise asymptomatic, underwent a nasopharyngeal swab before bronchoscopy, and all tested negative for SARS-CoV-2.

Symptomatology in our 10 SARS-CoV-2 positive patients was comparable to a nontransplanted population and in general was rather mild to moderate, except for one patient who had very severe disease and finally died after 2 weeks. In fact, although most patients had several risk factors for COVID-19 infection (Table 2), this specific patient had most of the accepted risk factors for severe disease and mortality, as mentioned in the literature: male sex, obesity (BMI 34.2), arterial hypertension for which he was treated with an angiotensin-converting enzyme (ACE) inhibitor, diabetes, and immunosuppressive treatment with tacrolimus, MMF, and CS. He also received the highest cumulative dose of immunosuppression, as he had been transplanted 190 months before the COVID-19 infection.

One patient, initially ambulatory when diagnosed, had late new onset of symptoms and needed hospitalization at a low care COVID-19 unit 6 weeks later. Remarkably, her nasopharyngeal swab was still positive after 6 weeks (with a comparable cycle threshold), and also the BAL fluid at admission was positive for SARS-CoV-2, whilst she developed ground glass opacities on CT scan. Despite this, the course of the disease flair up was favorable and she was discharged without oxygen supplement after 18 days.

All patients were at least on dual immunosuppressive treatment with a CNI and CS, whereas 60% were also taking a cell cycle inhibitor. Only these last drugs were stopped temporarily, whereas we did not change the CNI and CS dose. There has been a lot of debate so far about whether immunosuppressive treatment needs to be continued, lowered in dose, or even temporarily stopped in case of a COVID-19 infection. This question is still not resolved, although there is some evidence, specifically in a case series of liver transplant patients, that a higher trough level of CNI may result in a better outcome compared to very low levels. Indeed, in this series, three patients with a very low tacrolimus trough level died, whereas three others, who were more recently transplanted and hence had higher trough levels, survived. In addition, in the experience of the Columbia University kidney transplant group, the immunosuppressive medication was reduced in 15 COVID-19 kidney transplant cases, and 27% needed mechanical ventilation, but over half were discharged home by the end of follow-up. In another two kidney transplant patients, immunosuppressive treatment was left unchanged and both patients fully recovered. In 10 confirmed COVID-19 kidney transplant patients in Wuhan, the immunosuppressive treatment was reduced and the authors found that the severity of pneumonia was greater in the transplanted patients compared to the general population. Indeed five patients became severely ill and three critically ill, but finally 90% of their patients recovered, and only one died of progressive respiratory failure. In their series of 90 SOT patients with COVID-19, Pereira et al also maintained CNI and CS, but tapered/stopped cell cycle inhibitors. Based on these case series and our own results, it is difficult to decide whether immunosuppressive treatment has to be reduced upfront or can be continued at the same level (at least for CNI and CS) when COVID-19 is diagnosed. From our initial experience, it seems fair to say that the outcome without reduction of CNI and CS (but with temporarily arresting MMF and azathioprine) is acceptable. This is also in line with recommendations from the

### TABLE 2 Risk factors and laboratory data of the 10 patients

| Patient | Diagnostic PCR | BMI (kg/m²) | AHT | Diabetes | eGFR (mL/min/1.73 m²) | CRP (mg/L) | White cell count/LC | CNI trough level (µg/L) |
|---------|----------------|-------------|-----|----------|-----------------------|------------|---------------------|------------------------|
| 1       | NPS            | 29.3        | No  | NO       | 65                    | 6.3        | 3.45/0.5            | 8.3                    |
| 2       | BAL            | 30.5        | No  | NO       | 61                    | 138.3      | 10.28/1.0           | 14                     |
| 3       | NPS            | 21.8        | Yes | NO       | 20                    | 159.6      | 5.01/0.6            | 9.2                    |
| 4       | NPS            | 20.5        | Yes | NO       | 48                    | —          | —                   | 4.8                    |
| 5       | BAL            | 23.7        | No  | YES      | 110                   | 78.6       | 10.05/0.9           | 20.9                   |
| 6       | NPS            | 34.2        | Yes | YES      | 41                    | 156        | 4.5/0.3             | 9.4                    |
| 7       | NPS            | 27.2        | Yes | NO       | 47                    | 112.8      | 4.76/0.3            | 25.6                   |
| 8       | NPS            | 23.1        | Yes | YES      | 77                    | 5.5        | 4.23/1.1            | 89*                    |
| 9       | NPS            | 20.7        | no  | NO       | 31                    | 92.2       | 1.89/0.3            | 7.4                    |
| 10      | NPS            | 20.5        | no  | NO       | 62                    | 24.2       | 3.85/0.4            | 12.8                   |
| **Median (range)** |        | 23.4 (20.5-34.2) | 54.5 (20-110) | 92.2 (5.5-159.6) | 4.5 (1.89-10.28)/0.5 | FK: 9.4 (4.8-25.5) |

Abbreviations: AHT, arterial hypertension; BAL, bronchoalveolar lavage; CNI, calcineurin inhibitor; CRP, C-reactive protein; eGFR, estimated GFR; LC, absolute lymphocytosis; NPS, nasopharyngeal swab.

*Cyclosporine trough level (all others are tacrolimus).
COVID-19 task force from the International Society for Heart and Lung Transplantation.\textsuperscript{12}

For the time being, it can be concluded that we do not know yet whether classical immunosuppression may alter the predisposition to acquiring infection with SARS-CoV-2. This may well be the case as 1.5\% of our lung transplant cohort tested positive for SARS-CoV-2, whereas this was only 0.5\% in the general Belgian population. However, it must be argued that lung transplant patients come to see us with minor symptoms and will thus be swabbed, whereas this does not hold true for the general population. Whether the disease may become worse or not after lung transplantation\textsuperscript{13} is not clear, and in our small series the mortality rate was 10\% (1/10), whereas this was 16.2\% in the Belgian SARS-CoV-2 positive population, suggesting that COVID-19 may be somewhat more frequent after lung transplantation, but without a worse outcome, although these data should be interpreted with caution.

There is also some evidence that tacrolimus strongly inhibits the growth of human coronaviruses SARS-CoV, HCoV-NL63, and HCoV-229E at low, nontoxic concentrations, at least in cell cultures in vitro,\textsuperscript{14} which may again support the strategy to continue the CNI at the same dose. Furthermore, azithromycin has been suggested to be beneficial in the treatment of COVID-19 patients, at least when combined with hydroxychloroquine,\textsuperscript{15} which has been set as the standard treatment option in our center. Potential side effects when using this drug combination, especially QTc prolongation, need careful monitoring.\textsuperscript{15,16} Although hydroxychloroquine has been used widely in the treatment of COVID-19, it remains to be proven whether it is really beneficial in these patients. Several trials are running but convincing data are still lacking.\textsuperscript{16,17}

Remdesivir was recently shown to be superior to placebo in shortening the time to recovery in adults hospitalized with COVID-19 and evidence of lower respiratory tract infection and may become the treatment of choice.\textsuperscript{18} We were not able to use this drug as it is not yet available in Belgium.

In conclusion: this is a single-center report of COVID-19 infection in a series of 10 lung transplant patients. Besides a single patient with severe disease who died, disease presentation was mild/moderate in the other nine patients. One patient had a remarkable course as she was initially ambulatory and needed hospitalization 6 weeks later for recurrent and more severe COVID-19 disease, whereas she remained/became SARS-CoV-2 positive as well in the nasopharynx as in the BAL fluid.

We adapted the policy to temporarily arrest the cell cycle inhibitors, but not to reduce the CNI and CS treatment, which, according to our initial results, seems acceptable.

**ACKNOWLEDGMENTS**

We thank the Leuven lung transplant group for their valuable input.

**CONFLICT OF INTEREST**

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

**REFERENCES**

1. Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York [published online ahead of print 2020]. J Am Soc Nephrol. 2020;31(6):1150-1156. pii: ASN.2020030375.

2. Arpali E, Akyollu B, Yelken B, Tekin S, Turkmens A, Kocak B. Case report: a kidney transplant patient with mild COVID-19 [published online ahead of print 2020]. Transpl Infect Dis. 2020:e13296. https://doi.org/10.1111/tid.13296

3. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain [published online ahead of print 2020]. Am J Transplant. 2020;20(7):1849-1858.

4. Bussalino E, De Maria A, Russo R, Paolletti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report [published online ahead of print 2020]. Am J Transplant. 2020;20(7):1922-1924.

5. Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immnosuppressants management of coronavirus disease 2019 in solid organ transplant recipients [published online ahead of print 2020]. Am J Transplant. 2020;20(7):1916-1921.

6. Bhouri S, Rossi RE, Citterio D, Mazzafferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy [published online ahead of print 2020]. Lancet Gastroenterol Hepatol. 2020;5(6):532-533. pii: S2468-1253(20)30116-3.

7. Aigner C, Dittmer U, Collaud S, Taube C. Covid-19 in a lung transplant recipient [published online ahead of print 2020]. J Heart Lung Transplant. 2020;39(6):610-611. S1053–2498(20)31511-4.

8. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US Epicenter [published online ahead of print 2020]. Am J Transplant. 2020;20(7):1800-1808.

9. Tschopp J, H’Ullier AG, Mueller N-J, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in tehswiss transplant cohort study [published online ahead of print 2020]. Am J Transplant. 2020. https://doi.org/10.1111/ajt.16062

10. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis [published online ahead of print 2020]. J Infect. 2020. pii: S0163–4453(20)30234-6. https://doi.org/10.1016/j.jinf.2020.04.021

11. Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 30 confirmed cases in Wuhan, China [published online ahead of print 2020]. Eur Urol. 2020;77(6):748-754. pii: S0302–2838(20)30214-1.

12. ISHLT Covid-19 Task Force. Guidance from the International Society of Heart and Lung Transplantation regarding the SARS-CoV-2 pandemic. https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-centers-pdversion. Accessed April 18, 2020

13. Aslam S, Mehra MR. COVID-19: yet another coronavirus challenge in transplantation [published online ahead of print 2020]. J Heart Lung Transplant. 2020;39(5):408-409. pii: S1053–2498(20)31468-6.

14. Carbajo-Lozoya J, Müller MA, Kalies S, Thiel V, Drosten C, Von Brunn A. Replication of human coronaviruses SARS-CoV,
HcoV-NL63 and HcoV-229E is inhibited by the drug FK506. Virus Res. 2012;165:112-117.

15. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study [published online ahead of print 2020]. Travel Med Infect Dis. 2020;34:101663.

16. Chowdhury C, Rathod J, Gernsheimer J. A rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a treatment for COVID-19. Acad Emerg Med. 2020;6:493-504.

17. Wright C, Roos C, Mc GN. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (CVOVID-19)? Evid Based Dent. 2020;21:64-65.

18. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report [published online ahead of print 2020]. N Engl J Med. 2020. https://doi.org/10.1056/NEJMo a2007764

How to cite this article: Verleden GM, Godinas L, Lorent N, et al. COVID-19 in lung transplant patients: A case series. Am J Transplant. 2020;20:3234–3238. https://doi.org/10.1111/ajt.16212